By Christina T. Loguidice

Antibody-drug conjugates are innovative and effective therapeutic agents that have transformed the treatment landscape for patients with HER2-positive breast cancer and triple-negative breast cancer.

As investigators expand their understanding of the biology of endometrial cancer, doors to new treatment approaches are opening, including the use of a variety of combinations that employ targeted therapies and immunotherapies.

As CDK4/6 inhibitors solidify their role as the treatment of choice for patients with hormone receptor–positive, HER2-negative breast cancer, an ongoing clinical challenge remains: distinguishing the appropriate agent.

The degree to which nature and nurture affect disease has long been debated in medicine, and it is an issue that esteemed breast cancer researcher and medical oncologist Joyce A. O’Shaughnessy, MD, has been working to unravel for her patients throughout a career that spans more than 30 years.

During a recent OncLive Peer Exchange®, a panel of experts in adult and pediatric leukemias provided an update on minimal residual disease testing in acute lymphoblastic leukemia. 

A novel blood test identifies PAM4 (or clivatuzumab), an antigen that is present in almost 90% of pancreatic cancers and precancers.

While the concept of shrinking humans is quite fantastic and unrealistic, scientists have already developed tiny vessels that can hunt down diseased cells and deliver precise drug doses.